Gut bacteria capsule could tame fatty liver, early trial hopes
NCT ID NCT07488975
First seen Apr 09, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This early-stage study tests a probiotic capsule made from a pasteurized gut bacterium (Akkermansia muciniphila) in 40 adults with metabolic fatty liver disease (MASLD). The goal is to see if it safely reduces liver fat and scarring. Participants take different doses of the capsule or a placebo for 12 weeks, with follow-up scans to measure changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.